[Clinical and immunological changes in atopic dermatitis patients treated with purified staphylococcal toxoid].
32 patients with atopic dermatitis (AD), complicated by pyoderma, were treated with purified staphylococcal toxoid (PST). Changes in clinical and laboratory characteristics in the course of treatment were evaluated. PST was shown to produce a satisfactory therapeutic effect, arresting the symptoms of local staphylococcal infection. An increase in the levels of alpha- and gamma-interferons and decreased content of CD25+ lymphocytes were found. Thus prospects appear for using this preparation as an interferon inductor, as well a for the immunotherapy of AD patients sensitized to Staphylococcus aureus.
Mokronosova
M A
MA
Mechnikov Research Institute for Vaccines and Sera, Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, Russia.
Liaporova
T V
TV
Sergeev
A V
AV
Kopeĭkina
I V
IV
Ospel'nikova
T P
TP
Skhodova
S A
SA
D000293:Adolescent; D000328:Adult; D002648:Child; D003876:Dermatitis, Atopic / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000276:immunology; D011711:Pyoderma / Q000150:complications; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013203:Staphylococcal Infections / Q000209:etiology; D013208:Staphylococcal Toxoid / Q000627:therapeutic use*
D007369:Interferon Inducers; D016898:Interferon-alpha; D015375:Receptors, Interleukin-2; D013208:Staphylococcal Toxoid; D007371:Interferon-gamma